Status:
COMPLETED
Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Obesity, Morbid
Diabetes Mellitus Type 2
Eligibility:
All Genders
20-60 years
Brief Summary
This study will examine changes in various gut-derived hormones in obese type 2 diabetic patients before and after elective bariatric surgery.
Eligibility Criteria
Inclusion
- Documented type 2 diabetes with total disease duration ≤10 years
- BMI of at least 35 kg/m\^2
- Patient is a surgical candidate for either RYGBP, GBS or vertical sleeve gastrectomy (VSG)
Exclusion
- Any illness that might confound the results of the study or pose additional risk to the patient by participation
- History of stroke, seizures, or other major neurological disorder
- History of cancer
- Patient uses or has used any medication that can alter body weight
- Patient is unwilling or unable to follow study procedures
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00957957
Start Date
February 1 2010
End Date
November 1 2014
Last Update
January 20 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.